Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Glucarpidase
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved FDF
Sponsor : BTG Specialty Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Voraxaze® is a carboxypeptidase indicated to reduce toxic plasma methotrexate concentration (greater than 1 micromole per liter) in adult and pediatric patients with delayed methotrexate clearance due to impaired renal function.
Product Name : Megludase
Product Type : Enzyme
Upfront Cash : Inapplicable
September 28, 2021
Lead Product(s) : Glucarpidase
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved FDF
Sponsor : BTG Specialty Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable